Poniard Pharmaceuticals News

This article will discuss the development of Poniard's lead drug, picoplatin, for the treatment of small cell lung cancer [SCLC]. A General introduction for picoplatin can be found in the first part of this ...

Crime fighter John Walsh gets candid about his role on America's Most Wanted and what it means to him to continue the legacy of his murdered son. via Florida Trend

“This was a successful effort, and much of it was done in Palm Beach County.”

Scripps Florida and the Torrey Pines Institute for Molecular Studies have separately completed licensing deals for potential cancer treatments with small biotechnology companies in California, the research ... via Palm Beach Post

“We are pleased with the productive collaboration with Scripps Research, and we are continuing to build on the progress of this collaboration to identify compounds that have significant potential to treat cancer and other diseases”

Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, and The Scripps Research Institute, a non-profit biomedical research organization, today announced that an agreement has been ... via Freshnews

“The data from our ongoing Phase 2 trial could establish picoplatin as a platform product and provide a solid foundation for supporting additional registration trials, thereby expanding the potential of this product.”

Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin combination ... via MediLexicon

SOUTH SAN FRANCISCO, Calif., May 1, 2008 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. via Med Ad News

“These final Phase 2 data show that picoplatin extended survival in patients with small cell lung cancer refractory to, or relapsing within 6 months of first-line platinum based chemotherapy”

Main Category: Lung Cancer Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 24 Apr 2008 - 0:00 PDT printer friendly view / write opinions rate article Poniard ... via Medical News Today

“The data from our ongoing clinical study supports further development of an oral formulation of picoplatin”

These data are consistent with findings from preclinical oral bioavailability studies of picoplatin. via Earth Times

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate. via Rehab Management

“This agreement is a major step forward in the development of picoplatin as a commercial oncology product and to ensure that picoplatin is available to patients and oncologists once FDA approval is obtained”

Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, announced an agreement with W. C. Heraeus GmbH for the commercial manufacture and supply of picoplatin active pharmaceutical ... via BioSpace

Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, announced that preliminary data from a Phase 1 trial of an oral formulation of picoplatin in patients with solid tumors will be ... via MediLexicon

On February 25, The Wall Street Transcript interviewed George B. Zavoico, an Equity Research Analyst at Cantor Fitzgerald specializing in micro and small cap biotechnology, specialty pharmaceuticals, and ... via Seeking Alpha

Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's fourth quarter and year-end financial results and ... via Med Ad News

“The data we have generated with picoplatin in prostate cancer indicate a PSA (prostate specific antigen) response of 65 percent which suggests an improvement compared to docetaxel therapy alone”

The poster presentation includes safety and efficacy data from a dose-escalating Phase 1 study of picoplatin in combination with full-dose docetaxel with prednisone as a first-line treatment for metastatic ... via Earth Times